Process of preparing microspheres for sustained release having improved dispersibility and syringeability

a microsphere and dispersibility technology, applied in the direction of capsule delivery, drug composition, peptide/protein ingredients, etc., can solve the problems of reducing the stability of formulations, affecting health, and the phase separation method is problematic, and achieves the effect of high drug encapsulation efficiency, convenient mass production, and uniform size suitable for injection

Inactive Publication Date: 2007-11-15
DAEWOONG PHARM CO LTD +1
View PDF24 Cites 25 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013]It is therefore an object of the present invention to provide a process for preparing sustained release microspheres comprising a biodegradable polymer as a carrier and a bioactive drug, the microspheres being easy for mass production, not containing a residual toxic solvent, which is a problem of conventional methods of preparing sustained release microspheres, having high drug encapsulation efficiency, and having a uniform size suitable for injection.
[0014]The present inventors conducted intensive studies, and found that when microspheres, which are obtained by spray drying a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent, are suspended in an aqueous solution containing polyvinyl alcohol to remove the residual solvent, the microspheres have improved suspendability and syringeability and high drug encapsulation efficiency with no residual toxic solvent, thereby leading to the present invention.

Problems solved by technology

However, the phase separation method is problematic as follows.
Since the toxic solvent such as methylenechloride is not sufficiently removed by drying under pressure, the residual solvent reduces the stability of formulations, and may also be detrimental to health when administered to the body.
Also, the excessive use of non-solvent, such as freon, hexane, heptane, cyclohexane, and trichlorofluoromethane, for the solidification of embryonic microspheres is not cost-effective upon mass production and causes serious environmental contamination.
However, the procedure for preparing microparticles does not exclude the possibility of an interaction between the polymer and the drug and denaturation of the drug due to high temperature and high pressure upon melt-extrusion, and denaturation of the drug due to heat locally generated during cryopulverization.
This method is also difficult to use to make microspheres having a uniform size, which are thus easy to inject.
The two methods for preparing microspheres, in addition to the problems of residual solvent, difficulty in mass production and drug denaturation, have another disadvantage in that a biodegradable polymer used for the sustainable release of a drug is non-hydrophilic and thus poorly dispersible in an aqueous suspension for injection.
Most hydrophilic drugs leak in large amounts when dispersed in an aqueous phase, resulting in low encapsulation efficiency.
Typically, microspheres prepared by double emulsion evaporation are more porous than those prepared by single emulsion evaporation, and thus have increased surface areas, leading to a relatively high initial release rate of a drug.
However, the single and double emulsion evaporation methods for preparing microspheres, like the phase separation method, have the following disadvantages: difficulty in the removal of an organic solvent used for dissolving a biodegradable polymer, difficulty in mass production procedures due to changes in solvent removal rate, allergic reactions to gelatin used for increasing the viscosity of a primary emulsion, the possibility of a drug becoming denatured and losing its activity due to strong shearing force applied for making small microspheres during primary emulsion preparation, limited drug encapsulation, and the like.
The solvent used is not sufficiently removed merely by spray drying.
The residual solvent causes a problem in the stability of the biodegradable polymer upon long-term storage, leading to changes in drug release profiles of microspheres.
Another disadvantage of this method is that since biodegradable polymers used for drug encapsulation are mostly non-hydrophilic, microspheres prepared are not suspended well and are thus difficult to accurately administer.
As described above, most conventional methods of preparing sustained release microspheres employ a toxic solvent, and have problems including residue of the toxic solvent used, the microsphere size not being suitable for injection, poor suspendability of microspheres, and difficult mass production.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process of preparing microspheres for sustained release having improved dispersibility and syringeability
  • Process of preparing microspheres for sustained release having improved dispersibility and syringeability
  • Process of preparing microspheres for sustained release having improved dispersibility and syringeability

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

Preparation of Microspheres and a Post-Process Using Various Dispersing Agents

[0034]PLGA microspheres were prepared using a spray dryer (SODEVA, France) equipped with an ultrasonic nozzle (Sono-Tek, 120 kHz). A biodegradable polymer, RG503H (Boehringer-Ingelheim, Germany), and a drug, leuprolelin acetate (Polypeptide Laboratories, Denmark), were used. 50 g of RG503H and 2.5 g of leuprolelin acetate were homogeneously dissolved in 500 ml of glacial acetic acid (Yakuri Pure Chemicals, Japan). The solution was transported at a flow rate of 3 ml / min using a piston pump. The transported solution was sprayed into the spray drier through an ultrasonic nozzle installed in an upper part of a sprayer, and dried with dry air at 200° C. Thereafter, microspheres recovered from a cyclone were taken in a certain volume, weighed precisely, added at a concentration of 50 mg / ml to an aqueous solution containing distilled water and 1% (w / v) of a dispersing agent, and suspended therein for one hour at ...

preparation example 2

An Effect of Dispersal Time for Improving the Dispersibility of Microspheres

[0037]PLGA microspheres were prepared using a spray dryer (SODEVA, France) equipped with an ultrasonic nozzle (Sono-Tek, 120 kHz). A biodegradable polymer, RG503H, and a drug, leuprolelin acetate, were used. 40 g of RG503H and 4 g of leuprolelin acetate were homogeneously dissolved in 400 ml of glacial acetic acid. The solution was sprayed into a spray drier through an ultrasonic nozzle at a flow rate of 3 ml / min, and dried with dry air at 200° C. Thereafter, microspheres recovered from a cyclone were taken in a predetermined amount, added at a concentration of 50 mg / ml to an aqueous solution containing 1% (w / v) polyvinyl alcohol, and suspended therein for 1 min, 3 min, 5 min, 10 min, 1 hr, 3 hr and 6 hr at 25° C. using a magnetic agitator. The suspension was passed through a vacuum filter. Microspheres thus collected were washed with distilled water two times, and freeze-dried.

preparation example 3

Preparation of BSA-Loaded Microspheres by Spray Drying of W / O Type Emulsion Containing BSA

[0050]0.5 g of bovine serum albumin (BSA) (Sigma, A-7638) was dissolved in distilled water, and homogeneously mixed with a solution prepared by dissolving 9.5 g of RG502H in 95 ml of methylene chloride, thereby yielding a W / O type emulsion. While the emulsion was maintained in an emulsion state using an agitator, it was supplied to a spray drier (Buchi-191) at a flow rate of 3 ml / min. Compressed air was supplied to a two-fluid nozzle at a flow rate of 450 NL / h to dry sprayed atomized droplets using dry air at 80° C. The recovered microspheres were suspended for 3 hrs in an aqueous solution of 1% polyvinyl alcohol at a concentration of 50 mg / ml with agitation using a magnetic agitator, washed with distilled water, and freeze-dried. The microspheres thus prepared had a mean particle size of 5.2 μm, and the amount of polyvinyl alcohol remaining on the surface of the microspheres was 0.93% (w / w).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
dispersal timeaaaaaaaaaa
flow rateaaaaaaaaaa
concentrationaaaaaaaaaa
Login to view more

Abstract

Disclosed is a process of preparing sustained release microspheres, containing a biodegradable polymer as a carrier and a drug, using spray drying. The process comprises preparing a solution, suspension or emulsion containing a biodegradable polymer, a drug and a solvent; spray drying the solution, suspension or emulsion; and suspending spray-dried microspheres in an aqueous solution containing polyvinyl alcohol to remove the residual solvent and increase the hydrophilicity of the microsphere surface. The process enables the preparation of microspheres having high drug encapsulation efficiency, almost not having a toxicity problem due to the residual solvent, and having good syringeability. The microspheres prepared according to the present invention release an effective concentration of a drug in a sustained manner for a predetermined period when administered to the body, and are thus useful in the treatment of diseases.

Description

TECHNICAL FIELD[0001]The present invention relates to a process of preparing sustained release microspheres comprising a biodegradable polymer as a carrier and a drug. Such microspheres are an injectable sustained-release formulation, which enables the sustained and uniform release of a drug so as to maintain its biological activity in the body upon subcutaneous or intramuscular injection.BACKGROUND ART[0002]A number of approaches have been used to encapsulate bioactive agents into microspheres of polymers for sustained release. Most of them are based on phase separation (U.S. Pat. No. 4,673,595, EP 52,510), cryopulverization after melt extrusion (U.S. Pat. Nos. 5,134,122, 5,192,741, 5,225,205, 5,431,348, 5,439,688, 5,445,832 and 5,776,885), double emulsion evaporation (w / o / w, water / oil / water) (U.S. Pat. Nos. 4,652,441, 4,711,782, 4,954,298, 5,061,492, 5,330,767, 5,476,663, 5,480,656, 5,611,971, 5,631,020 and 5,631,021), single emulsion evaporation (o / w, oil / water) (U.S. Pat. Nos. 4...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/10
CPCA61K9/1694A61K9/1647A61K38/31A61K38/09A61K9/1635A61K31/765A61P43/00A61K9/48A61K9/08A61K9/10
Inventor LEE, HEE-YONGKIM, JUNG-SOOSHIN, EUN-HOKIM, SEONG-KYUSOEL, EUN-YOUNGBAEK, MI-JINBAEK, MI-YOUNGCHAE, YEON-JINCHOI, HO-IL
Owner DAEWOONG PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products